Madrigal Pharmaceuticals (MDGL) Short-term Investments (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Short-term Investments data on file, last reported at $5.2 million in Q1 2026.

• Short-term Investments for Q1 2026 came in at $5.2 million, down 99.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.2 million (down 99.22% YoY), and the FY2025 annual result was $5.1 million, up 2.0% from the prior year.
• Short-term Investments rose to $5.2 million in Q1 2026 per MDGL's latest filing, from $5.1 million in the prior quarter.
• Over five years, Short-term Investments peaked at $814.1 million in Q3 2025 and troughed at $5.0 million in Q4 2024.
• A 5-year average of $308.1 million and a median of $196.9 million in 2022 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2024 and 2026: Short-term Investments jumped 349.77% in 2024, then plunged 99.22% in 2026.
• A 5-year view of Short-term Investments shows it stood at $27.2 million in 2022, then soared by 525.51% to $170.3 million in 2023, then slumped by 97.06% to $5.0 million in 2024, then climbed by 2.0% to $5.1 million in 2025, then climbed by 1.08% to $5.2 million in 2026.
• Business Quant data shows MDGL's Short-term Investments at $5.2 million in Q1 2026, $5.1 million in Q4 2025, and $814.1 million in Q3 2025.